SGLT-2 inhibitors reduce dialysis risk: landmark study

Australian-led review finds the gliflozins reduce risk of death by 33%

SGLT-2 inhibitors reduce the risk of kidney dialysis, transplantation and death from kidney disease by one-third, a landmark Australian-led review has found.


The findings provide the strongest evidence yet that the drugs should be routinely offered to patients with type 2 diabetes at risk of progressive kidney disease, the researchers say.

Study co-author Associate Professor Meg Jardine, from the George Institute for Global Health in Sydney, says the meta-analysis of four major SGLT-2 trials,